Novel Patch for Transdermal Administration of Morphine
Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride...
Saved in:
| Published in | Journal of Pain and Symptom Management Vol. 44; no. 4; pp. 479 - 485 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York, NY
Elsevier Inc
01.10.2012
Elsevier BV Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0885-3924 1873-6513 1873-6513 |
| DOI | 10.1016/j.jpainsymman.2011.10.022 |
Cover
| Abstract | Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported.
To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs.
In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined.
Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC0–72) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64.
These data provide useful information for developing a transdermal morphine system. |
|---|---|
| AbstractList | Context: Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. Objectives: To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs. Methods: In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined. Results: Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180 mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC0-72) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4 +/- 13.4, 133.7 +/- 17.4, and 861.5 +/- 126.7 ngh/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64. Conclusions: These data provide useful information for developing a transdermal morphine system. [Copyright U.S. Cancer Pain Relief Committee. Published by Elsevier Inc.] Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs. In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined. Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC0–72) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64. These data provide useful information for developing a transdermal morphine system. Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported.CONTEXTTransdermal absorption of morphine into the systemic circulation through intact skin has not been reported.To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs.OBJECTIVESTo describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs.In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined.METHODSIn this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined.Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64.RESULTSMorphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64.These data provide useful information for developing a transdermal morphine system.CONCLUSIONThese data provide useful information for developing a transdermal morphine system. Abstract Context Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. Objectives To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs. Methods In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined. Results Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180 mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC0–72 ) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4 ± 13.4, 133.7 ± 17.4, and 861.5 ± 126.7 ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64. Conclusion These data provide useful information for developing a transdermal morphine system. Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. To describe a novel transdermal formulation for a morphine hydrochloride patch consisting of polyethylene sponge foam as the retaining agent and adjusted proportions of morphine hydrochloride and adjunctive drugs. In this study, the transdermal morphine hydrochloride patch was administered to intact skin in five subjects and the plasma concentrations of morphine and its metabolites were examined. Morphine was absorbed systemically, producing plasma morphine concentrations above the assay detection limit by at least 24 hours after attachment of patches containing a total dose of 180mg of morphine. The levels gradually increased in a time-dependent manner without serious events. The area under the concentration-time curve from 0 to 72 hours (AUC(0-72)) values for morphine, morphine-6-glucuronide, and morphine-3-glucuronide were 60.4±13.4, 133.7±17.4, and 861.5±126.7ng·h/mL, respectively. The mean plasma area under the concentration-time curve from 0 to 72 hours ratio for morphine-6-glucuronide relative to morphine was 2.64. These data provide useful information for developing a transdermal morphine system. |
| Author | Inui, Naoki Chida, Kingo Kimura, Takahito Takeuchi, Kazuhiko Uchida, Shinya Watanabe, Hiroshi Kato, Tatsuhisa |
| Author_xml | – sequence: 1 givenname: Naoki surname: Inui fullname: Inui, Naoki email: inui@hama-med.ac.jp organization: Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 2 givenname: Tatsuhisa surname: Kato fullname: Kato, Tatsuhisa organization: Teika Pharmaceutical Company Limited, Toyama, Japan – sequence: 3 givenname: Shinya surname: Uchida fullname: Uchida, Shinya organization: Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 4 givenname: Kingo surname: Chida fullname: Chida, Kingo organization: The Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 5 givenname: Kazuhiko surname: Takeuchi fullname: Takeuchi, Kazuhiko organization: Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan – sequence: 6 givenname: Takahito surname: Kimura fullname: Kimura, Takahito organization: Teika Pharmaceutical Company Limited, Toyama, Japan – sequence: 7 givenname: Hiroshi surname: Watanabe fullname: Watanabe, Hiroshi organization: Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan |
| BackLink | https://cir.nii.ac.jp/crid/1871709542927548800$$DView record in CiNii http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26446548$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22727949$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVktuLEzEUxoOsuN3Vf0FGUPBlai6Ty_iglOIN1gu4Poc0c8KmziTdZLrS_96MrRcWxPqSQPI7X06-852hkxADIPSI4DnBRDxbz9cb40PeDYMJc4oJKedzTOkdNCNKslpwwk7QDCvFa9bS5hSd5bzGGHMm2D10Sqmksm3aGRIf4g301Scz2qvKxVRdJhNyB2kwfbXoBh98HpMZfQxVdNX7mDZXPsB9dNeZPsODw36Ovrx-dbl8W198fPNuubioreRyrBvKHKxku6Kms2IliCBWlRtHHMYCKGucIxxLzhsFQmBrOCUcGKG4Ea3D7Bw93-tuw8bsvpm-15vkB5N2mmA9maHX-g8z9GTGdFXMKMVP98WbFK-3kEc9-Gyh702AuM2aEMqpYq1U_0axKoJKYVbQhwd0uxqg-9XPT08L8OQAmGxN74qh1uffnGgaUf5buHbP2RRzTuD-62svb9VaP_6YUhmW749SeLxXCN6X4mkt0SESt7yhLZWlQ4WnASz3GJQp33hIOlsPwULnE9hRd9Ef9diLWyq2L08Wd77CDvI6blMoMdJEZ6qx_jwFd8ptyQEmkogisPi7wJFNfAc5ff4H |
| CODEN | JSPME2 |
| CitedBy_id | crossref_primary_10_1016_j_ejpb_2015_09_013 crossref_primary_10_12923_j_2084_980X_26_1_a_19 crossref_primary_10_3390_plants12142661 crossref_primary_10_1016_j_crbiot_2022_10_005 crossref_primary_10_3109_03639045_2015_1071832 crossref_primary_10_3390_molecules23030681 crossref_primary_10_2147_IMCRJ_S259326 |
| Cites_doi | 10.1007/BF00637682 10.1016/S0304-3959(98)00211-5 10.1001/jama.1995.03530230056031 10.1111/j.1365-2125.1985.tb02675.x 10.1016/S0885-3924(98)00140-7 10.1038/clpt.1990.2 10.1016/j.ctrv.2006.03.001 10.1016/j.jpainsymman.2003.09.011 10.1016/0304-3959(89)90130-9 10.1211/jpp.59.7.0002 10.1016/j.jpainsymman.2007.04.016 10.1016/0140-6736(93)92900-E 10.1097/00000542-198906000-00008 10.1136/bmj.331.7520.825 10.1016/j.ejpain.2008.04.011 10.1200/JCO.2002.20.1.348 10.1023/A:1015944018555 10.1093/annonc/mdn108 10.1111/j.1365-2125.1994.tb04306.x 10.1046/j.1365-2125.2000.00141.x |
| ContentType | Journal Article |
| Copyright | 2012 U.S. Cancer Pain Relief Committee U.S. Cancer Pain Relief Committee 2015 INIST-CNRS Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2012 U.S. Cancer Pain Relief Committee – notice: U.S. Cancer Pain Relief Committee – notice: 2015 INIST-CNRS – notice: Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. |
| DBID | RYH AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7QJ ADTOC UNPAY |
| DOI | 10.1016/j.jpainsymman.2011.10.022 |
| DatabaseName | CiNii Complete CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Applied Social Sciences Index & Abstracts (ASSIA) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) |
| DatabaseTitleList | Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1873-6513 |
| EndPage | 485 |
| ExternalDocumentID | 10.1016/j.jpainsymman.2011.10.022 22727949 26446548 10_1016_j_jpainsymman_2011_10_022 S0885392412001716 1_s2_0_S0885392412001716 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M ..I .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29L 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACJTP ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXBA AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV BR6 CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FRJ FYGXN G-2 G-Q GBLVA HDV HMK HMO HVGLF HZ~ IHE J1W J5H KOM LX1 M29 M2W M41 MO0 MOBAO N9A O-L O9- OAUVE OG. OK1 OS- OZT P-8 P-9 P2P PC. Q38 QTD R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNG SNH SPCBC SSH SSN SSZ T5K TR2 UV1 WOW WUQ YYQ Z5R ZGI ZXP ~G- AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AADPK AAIAV ABLVK ABVKL ABYKQ AISVY AJBFU EFLBG LCYCR NAHTW AGRNS RYH AAYXX ACLOT CITATION ~HD IQODW CGR CUY CVF ECM EIF NPM 7X8 7QJ ADTOC UNPAY |
| ID | FETCH-LOGICAL-c757t-423feb79b2adc6b6161c8757f1f006e234ff15075548e660ca5215e3120469f03 |
| IEDL.DBID | .~1 |
| ISSN | 0885-3924 1873-6513 |
| IngestDate | Tue Aug 26 13:42:57 EDT 2025 Sun Sep 28 05:16:31 EDT 2025 Sat Sep 27 18:18:13 EDT 2025 Mon Jul 21 06:07:10 EDT 2025 Mon Jul 21 09:12:49 EDT 2025 Wed Oct 01 03:50:48 EDT 2025 Thu Apr 24 23:07:29 EDT 2025 Thu Jun 26 21:24:40 EDT 2025 Fri Feb 23 02:35:22 EST 2024 Sun Feb 23 10:19:06 EST 2025 Tue Aug 26 17:11:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | pharmacokinetics Morphine transdermal administration Delivery system Transdermal system Dosage form Opiates Narcotic analgesic Pharmacokinetics Patch Percutaneous route |
| Language | English |
| License | http://www.elsevier.com/open-access/userlicense/1.0 https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c757t-423feb79b2adc6b6161c8757f1f006e234ff15075548e660ca5215e3120469f03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=http://www.jpsmjournal.com/article/S0885392412001716/pdf |
| PMID | 22727949 |
| PQID | 1082238803 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | unpaywall_primary_10_1016_j_jpainsymman_2011_10_022 proquest_miscellaneous_1125283978 proquest_miscellaneous_1082238803 pubmed_primary_22727949 pascalfrancis_primary_26446548 crossref_primary_10_1016_j_jpainsymman_2011_10_022 crossref_citationtrail_10_1016_j_jpainsymman_2011_10_022 nii_cinii_1871709542927548800 elsevier_sciencedirect_doi_10_1016_j_jpainsymman_2011_10_022 elsevier_clinicalkeyesjournals_1_s2_0_S0885392412001716 elsevier_clinicalkey_doi_10_1016_j_jpainsymman_2011_10_022 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-10-01 |
| PublicationDateYYYYMMDD | 2012-10-01 |
| PublicationDate_xml | – month: 10 year: 2012 text: 2012-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York, NY |
| PublicationPlace_xml | – name: New York, NY – name: United States |
| PublicationTitle | Journal of Pain and Symptom Management |
| PublicationTitleAlternate | J Pain Symptom Manage |
| PublicationYear | 2012 |
| Publisher | Elsevier Inc Elsevier BV Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier BV – name: Elsevier |
| References | Paice, Von Roenn, Hudgins (bib11) 2008; 35 Calis, Kohler, Corso (bib5) 1992; 11 Krajnik, Zylicz, Finlay, Luczak, van Sorge (bib21) 1999; 80 Mercadante, Bruera (bib7) 2006; 32 Quigley (bib4) 2008; 2008 Ribeiro, Joel, Zeppetella (bib20) 2004; 27 Jadad, Browman (bib1) 1995; 274 Wang, Sung, Huang, Yeh, Fang (bib12) 2007; 59 Indelicato, Portenoy (bib6) 2002; 20 Twillman, Long, Cathers, Mueller (bib22) 1999; 17 Kress (bib9) 2009; 13 Osborne, Joel, Trew, Slevin (bib14) 1990; 47 Sawe, Kager, Svensson Eng, Rane (bib13) 1985; 19 Westerling, Hoglund, Lundin, Svedman (bib19) 1994; 37 Stuart-Harris, Joel, McDonald, Currow, Slevin (bib15) 2000; 49 Quigley (bib2) 2005; 331 Gourlay, Kowalski, Plummer (bib16) 1989; 37 Tennant, Moll, DePaulo (bib18) 1993; 342 Roy, Flynn (bib17) 1989; 6 Seibel, Barrett, Kirk, Heykants (bib10) 1987; 32 Varvel, Shafer, Hwang, Coen, Stanski (bib8) 1989; 70 Jost, Roila (bib3) 2008; 19 Quigley (10.1016/j.jpainsymman.2011.10.022_bib4) 2008; 2008 Gourlay (10.1016/j.jpainsymman.2011.10.022_bib16) 1989; 37 Jost (10.1016/j.jpainsymman.2011.10.022_bib3) 2008; 19 Varvel (10.1016/j.jpainsymman.2011.10.022_bib8) 1989; 70 Indelicato (10.1016/j.jpainsymman.2011.10.022_bib6) 2002; 20 Stuart-Harris (10.1016/j.jpainsymman.2011.10.022_bib15) 2000; 49 Westerling (10.1016/j.jpainsymman.2011.10.022_bib19) 1994; 37 Tennant (10.1016/j.jpainsymman.2011.10.022_bib18) 1993; 342 Krajnik (10.1016/j.jpainsymman.2011.10.022_bib21) 1999; 80 Mercadante (10.1016/j.jpainsymman.2011.10.022_bib7) 2006; 32 Ribeiro (10.1016/j.jpainsymman.2011.10.022_bib20) 2004; 27 Sawe (10.1016/j.jpainsymman.2011.10.022_bib13) 1985; 19 Seibel (10.1016/j.jpainsymman.2011.10.022_bib10) 1987; 32 Quigley (10.1016/j.jpainsymman.2011.10.022_bib2) 2005; 331 Roy (10.1016/j.jpainsymman.2011.10.022_bib17) 1989; 6 Wang (10.1016/j.jpainsymman.2011.10.022_bib12) 2007; 59 Jadad (10.1016/j.jpainsymman.2011.10.022_bib1) 1995; 274 Twillman (10.1016/j.jpainsymman.2011.10.022_bib22) 1999; 17 Calis (10.1016/j.jpainsymman.2011.10.022_bib5) 1992; 11 Paice (10.1016/j.jpainsymman.2011.10.022_bib11) 2008; 35 Kress (10.1016/j.jpainsymman.2011.10.022_bib9) 2009; 13 Osborne (10.1016/j.jpainsymman.2011.10.022_bib14) 1990; 47 |
| References_xml | – volume: 13 start-page: 219 year: 2009 end-page: 230 ident: bib9 article-title: Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine publication-title: Eur J Pain – volume: 274 start-page: 1870 year: 1995 end-page: 1873 ident: bib1 article-title: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation publication-title: JAMA – volume: 80 start-page: 121 year: 1999 end-page: 125 ident: bib21 article-title: Potential uses of topical opioids in palliative care—report of 6 cases publication-title: Pain – volume: 342 start-page: 1047 year: 1993 end-page: 1048 ident: bib18 article-title: Topical morphine for peripheral pain publication-title: Lancet – volume: 32 start-page: 304 year: 2006 end-page: 315 ident: bib7 article-title: Opioid switching: a systematic and critical review publication-title: Cancer Treat Rev – volume: 49 start-page: 207 year: 2000 end-page: 214 ident: bib15 article-title: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine publication-title: Br J Clin Pharmacol – volume: 32 start-page: 529 year: 1987 end-page: 531 ident: bib10 article-title: Transdermal absorption of fentanyl and sufentanil in man publication-title: Eur J Clin Pharmacol – volume: 19 start-page: 495 year: 1985 end-page: 501 ident: bib13 article-title: Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation publication-title: Br J Clin Pharmacol – volume: 37 start-page: 571 year: 1994 end-page: 576 ident: bib19 article-title: Transdermal administration of morphine to healthy subjects publication-title: Br J Clin Pharmacol – volume: 70 start-page: 928 year: 1989 end-page: 934 ident: bib8 article-title: Absorption characteristics of transdermally administered fentanyl publication-title: Anesthesiology – volume: 27 start-page: 434 year: 2004 end-page: 439 ident: bib20 article-title: The bioavailability of morphine applied topically to cutaneous ulcers publication-title: J Pain Symptom Manage – volume: 17 start-page: 288 year: 1999 end-page: 292 ident: bib22 article-title: Treatment of painful skin ulcers with topical opioids publication-title: J Pain Symptom Manage – volume: 35 start-page: 314 year: 2008 end-page: 320 ident: bib11 article-title: Morphine bioavailability from a topical gel formulation in volunteers publication-title: J Pain Symptom Manage – volume: 6 start-page: 825 year: 1989 end-page: 832 ident: bib17 article-title: Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin publication-title: Pharm Res – volume: 11 start-page: 22 year: 1992 end-page: 36 ident: bib5 article-title: Transdermally administered fentanyl for pain management publication-title: Clin Pharm – volume: 19 start-page: ii119 year: 2008 end-page: ii121 ident: bib3 article-title: Management of cancer pain: ESMO clinical recommendations publication-title: Ann Oncol – volume: 47 start-page: 12 year: 1990 end-page: 19 ident: bib14 article-title: Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide publication-title: Clin Pharmacol Ther – volume: 331 start-page: 825 year: 2005 end-page: 829 ident: bib2 article-title: The role of opioids in cancer pain publication-title: BMJ – volume: 20 start-page: 348 year: 2002 end-page: 352 ident: bib6 article-title: Opioid rotation in the management of refractory cancer pain publication-title: J Clin Oncol – volume: 2008 year: 2008 ident: bib4 article-title: Opioids in people with cancer-related pain publication-title: Clin Evid (Online) – volume: 37 start-page: 193 year: 1989 end-page: 202 ident: bib16 article-title: The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects publication-title: Pain – volume: 59 start-page: 917 year: 2007 end-page: 925 ident: bib12 article-title: Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study publication-title: J Pharm Pharmacol – volume: 32 start-page: 529 year: 1987 ident: 10.1016/j.jpainsymman.2011.10.022_bib10 article-title: Transdermal absorption of fentanyl and sufentanil in man publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00637682 – volume: 80 start-page: 121 year: 1999 ident: 10.1016/j.jpainsymman.2011.10.022_bib21 article-title: Potential uses of topical opioids in palliative care—report of 6 cases publication-title: Pain doi: 10.1016/S0304-3959(98)00211-5 – volume: 274 start-page: 1870 year: 1995 ident: 10.1016/j.jpainsymman.2011.10.022_bib1 article-title: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation publication-title: JAMA doi: 10.1001/jama.1995.03530230056031 – volume: 19 start-page: 495 year: 1985 ident: 10.1016/j.jpainsymman.2011.10.022_bib13 article-title: Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1985.tb02675.x – volume: 17 start-page: 288 year: 1999 ident: 10.1016/j.jpainsymman.2011.10.022_bib22 article-title: Treatment of painful skin ulcers with topical opioids publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(98)00140-7 – volume: 47 start-page: 12 year: 1990 ident: 10.1016/j.jpainsymman.2011.10.022_bib14 article-title: Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1990.2 – volume: 32 start-page: 304 year: 2006 ident: 10.1016/j.jpainsymman.2011.10.022_bib7 article-title: Opioid switching: a systematic and critical review publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2006.03.001 – volume: 11 start-page: 22 year: 1992 ident: 10.1016/j.jpainsymman.2011.10.022_bib5 article-title: Transdermally administered fentanyl for pain management publication-title: Clin Pharm – volume: 27 start-page: 434 year: 2004 ident: 10.1016/j.jpainsymman.2011.10.022_bib20 article-title: The bioavailability of morphine applied topically to cutaneous ulcers publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2003.09.011 – volume: 37 start-page: 193 year: 1989 ident: 10.1016/j.jpainsymman.2011.10.022_bib16 article-title: The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects publication-title: Pain doi: 10.1016/0304-3959(89)90130-9 – volume: 59 start-page: 917 year: 2007 ident: 10.1016/j.jpainsymman.2011.10.022_bib12 article-title: Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study publication-title: J Pharm Pharmacol doi: 10.1211/jpp.59.7.0002 – volume: 35 start-page: 314 year: 2008 ident: 10.1016/j.jpainsymman.2011.10.022_bib11 article-title: Morphine bioavailability from a topical gel formulation in volunteers publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2007.04.016 – volume: 342 start-page: 1047 year: 1993 ident: 10.1016/j.jpainsymman.2011.10.022_bib18 article-title: Topical morphine for peripheral pain publication-title: Lancet doi: 10.1016/0140-6736(93)92900-E – volume: 70 start-page: 928 year: 1989 ident: 10.1016/j.jpainsymman.2011.10.022_bib8 article-title: Absorption characteristics of transdermally administered fentanyl publication-title: Anesthesiology doi: 10.1097/00000542-198906000-00008 – volume: 331 start-page: 825 year: 2005 ident: 10.1016/j.jpainsymman.2011.10.022_bib2 article-title: The role of opioids in cancer pain publication-title: BMJ doi: 10.1136/bmj.331.7520.825 – volume: 13 start-page: 219 year: 2009 ident: 10.1016/j.jpainsymman.2011.10.022_bib9 article-title: Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine publication-title: Eur J Pain doi: 10.1016/j.ejpain.2008.04.011 – volume: 20 start-page: 348 year: 2002 ident: 10.1016/j.jpainsymman.2011.10.022_bib6 article-title: Opioid rotation in the management of refractory cancer pain publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.1.348 – volume: 6 start-page: 825 year: 1989 ident: 10.1016/j.jpainsymman.2011.10.022_bib17 article-title: Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin publication-title: Pharm Res doi: 10.1023/A:1015944018555 – volume: 19 start-page: ii119 issue: Suppl 2 year: 2008 ident: 10.1016/j.jpainsymman.2011.10.022_bib3 article-title: Management of cancer pain: ESMO clinical recommendations publication-title: Ann Oncol doi: 10.1093/annonc/mdn108 – volume: 37 start-page: 571 year: 1994 ident: 10.1016/j.jpainsymman.2011.10.022_bib19 article-title: Transdermal administration of morphine to healthy subjects publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.1994.tb04306.x – volume: 2008 year: 2008 ident: 10.1016/j.jpainsymman.2011.10.022_bib4 article-title: Opioids in people with cancer-related pain publication-title: Clin Evid (Online) – volume: 49 start-page: 207 year: 2000 ident: 10.1016/j.jpainsymman.2011.10.022_bib15 article-title: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine publication-title: Br J Clin Pharmacol doi: 10.1046/j.1365-2125.2000.00141.x |
| SSID | ssj0005363 ssib006545544 ssib013958349 |
| Score | 2.0807858 |
| Snippet | Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported.
To describe a novel transdermal formulation for a... Abstract Context Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. Objectives To describe a novel... Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported.CONTEXTTransdermal absorption of morphine into the... Context: Transdermal absorption of morphine into the systemic circulation through intact skin has not been reported. Objectives: To describe a novel... |
| SourceID | unpaywall proquest pubmed pascalfrancis crossref nii elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 479 |
| SubjectTerms | Absorption Administration, Cutaneous Aged Anesthesia & Perioperative Care Area Under Curve Attachment Biological and medical sciences Biological Availability Detection Dosage Humans Male Medical sciences Middle Aged Morphine Morphine - administration & dosage Morphine - blood Morphine - pharmacokinetics Pain Medicine pharmacokinetics Pharmacology. Drug treatments transdermal administration Transdermal Patch |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aFLrtYd_rvK3Fhb26teXvsZcyVsogobAF2ifhD4k2S2xTJxvdX7_fVXba0m5kezEE6yTnftLdT-h0R_TezYJI60A7fpkoBx5POHCC2tGRUHGecn4Zvo08HEVH4-DLSXiyRn2VPo6qnDTtrFPklanuVLj_FQsiRGeBJ0yWl_2m1Ou0EfHR0oA2xqPjg1NDGkOH2_FeK4l9Jwo9f5N2r0O7Jg123e3lbJZVJoknx3cJ8SfXtF6dn3PMZNZCbdrUu7iPkD6iB4uqyS5_ZtPpDSd1-IRO-6s-Jjbl-95inu8Vv-5mfvzn__-UHnfM1T4w7Z7Rmqqe0-awO5t_QdGo_qGm9jFs-5kNKmxfucGSLT-kbuXotWttD2sgDMGXND78_O3TkdNVZXCKOIznDviXVnmc5iIriyiPQBkLzoqvPY0VrIQfaM0sEzwlUcCmyMAQQuXjq7EV167_igZVXanXZCdu6uoyFDqNNUtlQYGpgQFAJHLhKouSHhBZdCnLuXLGVPaxaRN5A0vJWPIrYGmRWIo2Jm_HKkIfetRlfzEVplTCu6wiHN8nrNoOy1Z6shXSlXdwtOjjUrLjPYbPrDrwNiYoFMRPTHgvBm3mKmRxyNbZtWjn1tRd6oO5cIQ2Fu32c1nCuPCJUVapetFy9ljQR3Ti_6UNKDI4ahqjny2zEK5HEKDHaZBa5C9XxupwvPkvqbf0EL-ECbh8R4P5xUJtgzjO853ORvwGitJnDA priority: 102 providerName: Unpaywall |
| Title | Novel Patch for Transdermal Administration of Morphine |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0885392412001716 https://www.clinicalkey.es/playcontent/1-s2.0-S0885392412001716 https://dx.doi.org/10.1016/j.jpainsymman.2011.10.022 https://cir.nii.ac.jp/crid/1871709542927548800 https://www.ncbi.nlm.nih.gov/pubmed/22727949 https://www.proquest.com/docview/1082238803 https://www.proquest.com/docview/1125283978 http://www.jpsmjournal.com/article/S0885392412001716/pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-6513 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005363 issn: 1873-6513 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-6513 dateEnd: 20221002 omitProxy: true ssIdentifier: ssj0005363 issn: 1873-6513 databaseCode: AIKHN dateStart: 19970601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-6513 dateEnd: 20221002 omitProxy: true ssIdentifier: ssj0005363 issn: 1873-6513 databaseCode: ACRLP dateStart: 19970601 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-6513 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005363 issn: 1873-6513 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-6513 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005363 issn: 1873-6513 databaseCode: AKRWK dateStart: 19861201 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fi9NAEB7OE059EH8b9UoOfI1NN8luI76U4lF_tBS1cD4tSbqLPXpJMa1yL_7tftMkvRZPKfiSkHRnl347O_MtmZ0heuknobQ2tF4w7RoPHk94cILWs1IYlcacX4ZPIw9HcjAJ359FZwfUb87CcFhlbfsrm7621vWbdo1mezGbtT9jfUToO-yIKukLn2APJYf1vfq1FeYRVNXU0Njj1kd0chXjdb7A9ru8vLhI8iqbJwd6CfE3H3Ujn804eDIpgZ-tCl9cx0zv0K1Vvkgufybz-Za3Or1Hd2ua6faqf3KfDkz-gI6G9Yf0hyRHxQ8zd8cwxN9c8FZ37bOmbKYhtZNQ1y2sOywwHRB8RJPTt1_6A68uoeBlKlJLD2TJmlTFqUimmUwl-F3GKextx2K5GRGE1jIlBKnoGin9LIE7j0wATLFvtn7wmA7zIjdPye36sW-nkbCxsiyVhBnmEQPA66fCNw51G9B0VucX5zIXc90Ekp3rLbw1480_AW-HxEZ0USXZ2EfodTMzujlFCrun4Qr2EVbXCZuyXsGl7uhSaF__oWUOvdlI7ijqvgMfQ4kAEF872K0qcFwuGaYiNqW-Q60d9drgwcRVoo1DJ42-aVgC_ryT5KZYlZzqFVwPnQT_aAM-C0IZK_TzpFLWqxEEuGwcxg4FG-3dfzqe_R8uz-k2nkQVJvmCDpffV-YYdG-ZttbruUU3e_1PH8d8f_dhMMJ9Mhr3vv4GiuZT6Q |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fT9swED5BkWA8oP0mY7Ag7TVq6iROM-0FoaEyaDVpIPFmJaktikpSLS2I_37f4aSlGpsq7SUPic9WPp_vPsvnO6LPfhpKY0LjBcOu9uDxhAcnaDwjhY6zhPPL8G3k_kD2LsPvV9HVGh03d2E4rLK2_damP1rr-k27RrM9GY3aP7E-IvQddoRN-rJOG2EEm9yijaPTs95gEekR2IJqaO-xwCYdLsK8bibYgVcPt7dpYRN6cqyXEH9zU-vFaMTxk2kFCI2tffEcOd2mrVkxSR_u0_H4icM6eUk7NdN0j-zPvKI1XbymzX59lv6G5KC802P3B2zxtQvq6j66rSFbakgt5dR1S-P2S8wIBN_S5cm3i-OeV1dR8PI4iqce-JLRWZxkIh3mMpOgeDlnsTcdgxWnRRAaw6wQvKKrpfTzFB490gFgxdbZ-ME7ahVloXfJ7fqJb4aRMElsWCoNc0wlBoDjz4SvHeo2oKm8TjHOlS7Gqoklu1FP8FaMN38C3g6JuejE5tlYRehLMzOquUgK06fgDVYRjp8T1lW9iCvVUZVQvvpD0Rz6Opdc0tVVB96HEgEgfnawYY1Bc7lqWByxNfUdOlhSrzkezF0l2jh02OibgjHgE5600OWs4myvoHvoJPhHG1BacMokRj_vrbIuRhCgs0mYOBTMtXf16fjwf7h8oq3eRf9cnZ8OzvboBb4IGzX5kVrTXzO9D_Y3zQ7q1f0buHVTTw |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aFLrtYd_rvK3Fhb26teXvsZcyVsogobAF2ifhD4k2S2xTJxvdX7_fVXba0m5kezEE6yTnftLdT-h0R_TezYJI60A7fpkoBx5POHCC2tGRUHGecn4Zvo08HEVH4-DLSXiyRn2VPo6qnDTtrFPklanuVLj_FQsiRGeBJ0yWl_2m1Ou0EfHR0oA2xqPjg1NDGkOH2_FeK4l9Jwo9f5N2r0O7Jg123e3lbJZVJoknx3cJ8SfXtF6dn3PMZNZCbdrUu7iPkD6iB4uqyS5_ZtPpDSd1-IRO-6s-Jjbl-95inu8Vv-5mfvzn__-UHnfM1T4w7Z7Rmqqe0-awO5t_QdGo_qGm9jFs-5kNKmxfucGSLT-kbuXotWttD2sgDMGXND78_O3TkdNVZXCKOIznDviXVnmc5iIriyiPQBkLzoqvPY0VrIQfaM0sEzwlUcCmyMAQQuXjq7EV167_igZVXanXZCdu6uoyFDqNNUtlQYGpgQFAJHLhKouSHhBZdCnLuXLGVPaxaRN5A0vJWPIrYGmRWIo2Jm_HKkIfetRlfzEVplTCu6wiHN8nrNoOy1Z6shXSlXdwtOjjUrLjPYbPrDrwNiYoFMRPTHgvBm3mKmRxyNbZtWjn1tRd6oO5cIQ2Fu32c1nCuPCJUVapetFy9ljQR3Ti_6UNKDI4ahqjny2zEK5HEKDHaZBa5C9XxupwvPkvqbf0EL-ECbh8R4P5xUJtgzjO853ORvwGitJnDA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+Patch+for+Transdermal+Administration+of+Morphine&rft.jtitle=Journal+of+pain+and+symptom+management&rft.au=Inui%2C+Naoki&rft.au=Kato%2C+Tatsuhisa&rft.au=Uchida%2C+Shinya&rft.au=Chida%2C+Kingo&rft.date=2012-10-01&rft.pub=Elsevier+Inc&rft.issn=0885-3924&rft.eissn=1873-6513&rft.volume=44&rft.issue=4&rft.spage=479&rft.epage=485&rft_id=info:doi/10.1016%2Fj.jpainsymman.2011.10.022&rft.externalDocID=S0885392412001716 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F08853924%2FS0885392412X00095%2Fcov150h.gif |